索利那新治疗膀胱过度活动症疗效观察

Effect observation of Solifenacin in treating overactive bladder

目的评价索利那新治疗膀胱过度活动症的疗效及其安全性。方法将泌尿外科就诊的膀胱过度活动症的患者180例随机平分为试验组和对照组,试验组给予索利那新每日1次,每次5 mg,晚饭后口服,疗程6周;对照组给予托特罗定每日2次,每次2 mg,早晚饭后口服,疗程6周。分别记录治疗前后24 h的排尿次数、平均每次尿量、最大膀胱容量和最大尿流率,评价索利那新的疗效,通过主要不良反应发生率评价其安全性。结果试验组24 h的排尿次数、平均尿量、最大膀胱容量和最大尿流率较对照组改善明显(P<0.05),试验组不良反应的发生率较对照组低(P<0.05)。结论索利那新治疗膀胱过度活动症疗效确切,安全性高。

[ Objective ] To evaluate the efficacy and safety of Solifenacin in treating patients with overactive blad- der （OAB）. [Methods] The study was a randomized trial. 180 patients with OAB were enrolled in the clinical trial, where 90 patients were assigned to receive Solifenacin （5 mg once daily after dinner for 6 weeks） and 90 were assigned to receive toherodine （2 mg twice daily after breakfast and dinner for 6 weeks）. After 6 weeks＇ treatment, the improvement of daily micturition frequency, average urine output, maximum cystometric capacity and maximum flow rate were used to evaluate the efficacy of Solifenacin. We evaluated the safety of Solifenacin by comparing the rate of adverse drug reactions between the two groups. [Results] The daily micturition frequency, average urine output, maximum cystometric capacity and maximum flow rate were significantly improved in the patients with OAB receiv- ing Solifenacin, as compared with the patients receiving Toherodine （P 〈0.05）. The rate of adverse drug reactions in the patients with OAB receiving Solifenacin were lower than that in the patients receiving Toherodin （P 〈0.05）. [ Conclusions ] Solifenacin could be a safer and more effective drug in the treatment of OAB.